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Abstract
Introduction: Mammary-specific overexpression of Six1 in mice induces tumors that resemble human breast
cancer, some having undergone epithelial to mesenchymal transition (EMT) and exhibiting stem/progenitor cell
features. Six1 overexpression in human breast cancer cells promotes EMT and metastatic dissemination. We
hypothesized that Six1 plays a role in the tumor initiating cell (TIC) population specifically in certain subtypes of
breast cancer, and that by understanding its mechanism of action, we could potentially develop new means to
target TICs.
Methods: We examined gene expression datasets to determine the breast cancer subtypes with Six1
overexpression, and then examined its expression in the CD24low/CD44+ putative TIC population in human luminal
breast cancers xenografted through mice and in luminal breast cancer cell lines. Six1 overexpression, or
knockdown, was performed in different systems to examine how Six1 levels affect TIC characteristics, using gene
expression and flow cytometric analysis, tumorsphere assays, and in vivo TIC assays in immunocompromised and
immune-competent mice. We examined the molecular pathways by which Six1 influences TICs using genetic/
inhibitor approaches in vitro and in vivo. Finally, we examined the expression of Six1 and phosphorylated
extracellular signal-regulated kinase (p-ERK) in human breast cancers.
Results: High levels of Six1 are associated with adverse outcomes in luminal breast cancers, particularly the luminal
B subtype. Six1 levels are enriched in the CD24low/CD44+ TIC population in human luminal breast cancers
xenografted through mice, and in tumorsphere cultures in MCF7 and T47D luminal breast cancer cells. When
overexpressed in MCF7 cells, Six1expands the TIC population through activation of transforming growth factor-beta
(TGF-b) and mitogen activated protein kinase (MEK)/ERK signaling. Inhibition of ERK signaling in MCF7-Six1 cells
with MEK1/2 inhibitors, U0126 and AZD6244, restores the TIC population of luminal breast cancer cells back to that
observed in control cells. Administration of AZD6244 dramatically inhibits tumor formation efficiency and
metastasis in cells that express high levels of Six1 ectopically or endogenously. Finally, we demonstrate that Six1
significantly correlates with phosphorylated ERK in human breast cancers.
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Conclusions: Six1 plays an important role in the TIC population in luminal breast cancers and induces a TIC
phenotype by enhancing both TGF-b and ERK signaling. MEK1/2 kinase inhibitors are potential candidates for
targeting TICs in breast tumors.
Introduction
Six1 is a homeodomain-containing transcription factor
that belongs to the Six family of homeoproteins and is
highly expressed in embryogenesis. The Six family mem-
bers are known to play an important role in the expan-
sion of precursor populations prior to differentiation
[1-4]. In mice, absence of Six1 leads to the reduction in
size or loss of multiple organs as a result of decreased
proliferation and increased apoptosis [5-10]. Thus, inap-
propriate expression of the Six genes in adult tissue has
the potential to contribute to tumor initiation. In sup-
port of this hypothesis, we have shown that aberrant
expression of Six1 in adult mammary cells reinstates a
pro-proliferative and pro-survival program that likely
contributes to Six1-dependent transformation and
tumor formation in xenograft and transgenic mouse
models [11-13].
Six1 mRNA is overexpressed in 50% of primary breast
cancers, and in a much larger 90% percent of metastatic
lesions [14], suggesting that it may be involved in more
than just tumor initiation. Indeed, our analysis of Six1
expression in several public microarray datasets from
human breast cancers demonstrates that inappropriate
overexpression of Six1 correlates significantly with
worse survival [12]. We recently determined that, in
addition to the role that Six1 plays in proliferation and
survival, its overexpression also leads to the induction of
an epithelial to mesenchymal transition (EMT) via upre-
gulation of transforming growth factor-b (TGF-b) sig-
naling. Since genes that induce EMT have been shown
to increase the metastatic capability of cells [15,16], we
previously investigated and demonstrated that Six1 over-
expression in mammary carcinoma cells induces metas-
tasis in both experimental and orthotopic mouse models
of metastasis [12]. Interestingly, Six1 overexpression in
the non-transformed mammary glands of transgenic
mice leads to an increase in the mammary stem cell
population, suggesting that Six1 may play a role in nor-
mal mammary stem cells [13]. Taken together, these
data suggest that Six1 overexpression in mammary car-
cinoma cells may increase the cancer stem cell (CSC) or
tumor initiating cell (TIC) population.
Herein we demonstrate for the first time that Six1
expression predicts poor prognosis, specifically in lumi-
nal subtypes of breast cancer where it is associated with
the CSC population. Indeed, we show that Six1 can lead
to the expansion of a luminal cancer stem-like cell, and
that it does so via its ability to activate both the TGF-b
signaling and mitogen activated protein kinase/extracel-
lular signal-regulated kinase (MEK/ERK) signaling path-
ways. We further demonstrate that the MEK1/2
inhibitor, AZD6244, significantly reduces tumor initiat-
ing capability in vivo in breast cancer cells that ectopi-
cally and endogenously express high levels of Six1.
Finally, we demonstrate that Six1 expression correlates
with phosphorylated ERK (pERK) levels in human breast
cancers, suggesting that Six1 mediates its tumor promo-
tional activities through activation of both TGF-b (pre-
viously shown) [12] and MEK/ERK signaling in the
human context. Taken together, our data present the
novel finding that Six1 mediates an increase in the TIC
population in luminal breast cancers via activating mul-
tiple signaling pathways.
Materials and methods
Cell culture
All cell lines were obtained from ATCC (American Type
Culture Collection, Manassas VA, USA) and cultured
per recommendations. Generation of MCF7-Ctrl,
MCF7-Six1, and MCF7-Six1-TbRIIDN lines was
described previously [12,17]. To tag the cells, one of
three MCF7-Ctrl (B1) and MCF7-Six1 (A13) clones was
transduced with pLNCX2-ZsGreen retrovirus and
selected by fluorescence activated cell sorting (FACS).
To generate 66cl4/Six1 KD cells, the cells were infected
with a lentiviral vector encoding either a scramble con-
trol or an shRNA targeting Six1 (Open Biosystems,
Lafayette CO, USA). Clonal isolates were chosen from
the two most efficient knockdown clones, Six1 KD1 (5’
AAACCCAGGGCTGCCTTGGAAAAG 3’) and Six1
KD2 (5’ AAACCCAGGGCTGCCTTGGAAAAG 3’), as
assessed by examining both RNA and protein levels.
Microarray analysis
Microarray analysis was previously performed as
described [12]. The red, green and black color scale
represents the expression level of a gene above, below
and equal, respectively, to the mean expression of that
probe across all samples. MCF7-Ctrl and MCF7-Six1
microarray data sets can be found in the NCBI GEO
database. The accession number is GSE23655. All gene
expression and clinical data from the 779 tumor dataset
and UNC311 dataset is available [18] under the collec-
tion of publications: Harrell et al., Breast Cancer
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Research and Treatment 2012 and Prat et al., Breast
Cancer Research 2010. Categorical survival analyses
were performed using log-rank tests and visualized with
Kaplan-Meier plots. Box-and-whisker plots show the
relationship of the intrinsic subtypes with Six1 and were
performed in R. Interquartile range (IQR) is shown by
the colored box and the bar indicates the median value;
whiskers are 1.5*IQR.
Immunohistochemistry
Tumor arrays containing human breast invasive ductal
cancer, with 71 cases/72 cores (US Biomax, BRC711,
Rockville MD, USA) were treated as previously
described [12,13]. The following primary antibodies
were used: Six1 (1:100 Atlas Antibodies, Stockholm,
Sweden) [12] and p-ERK (1:100 Phosphosolutions, Aur-
ora CO, USA).
Flow cytometry
Cultured cells or xenograft tumors were harvested and
washed in 0.5% BSA-PBS after which 106 cells were
stained in 20 ul of antibody on ice for 30 minutes. Cells
were washed in 1 ml of 0.5% BSA-PBS and resuspended
in 400 ul of 1 ug/ml DAPI/0.5% BSA-PBS after which
flow cytometry was performed. The following antibodies
were used; APC-linked anti human CD44 (1:1, #559942:
BD Pharmingen, San Jose CA, USA), biotin-linked anti
human CD24 (1:100, #13-0247-82; eBioscience, San
Diego CA, USA), and PE-linked streptavidin (1:200,
#554061; BD Biosciences-Pharmingen, San Jose CA,
USA). Fluorescence was detected with CyAn (Beckman
Coulter, Brea CA, USA).
Tumorsphere assay
Tumorsphere assays were performed as described in
Dontu et al. [19] with cells seeded at a density of 2000
cells/2 ml in 6-well dishes. For the single cell sphere
assay, single cells from the primary tumorspheres (1
cell/200 μl/well) were plated out in 96-well ultra-low
attachment plates (Costar, Austin TX, USA) and spheres
counted at 10 to 14 days.
Western blot analysis
Western blot analysis was performed on whole cell
lysates prepared as previously described [20] or with
nuclear extracts. The following primary antibodies were
used: E-cadherin (1:2500, #610181, BD Biosciences, San
Jose CA, USA), b-catenin (1:750, #610154, BD Bios-
ciences, San Jose CA, USA), p-ERK (1:1000, #9101S, Cell
Signaling, Danvers MA, USA), total ERK (1:1000, #9102,
Cell Signaling, Danvers MA, USA), b-actin (1:5000,
Sigma, St. Louis MO, USA), and Six1 (1;1000), which was
made as previously described [20]. Quantitation was
performed using the Quantity One version 4.6.2 software
(Bio-Rad, Hercules CA, USA).
Xenograft models
Breast tumors were collected after surgical resection at
The University of Colorado Hospital. Female NOD-scid
IL2Rgnull mice four- to seven-weeks old were purchased
from Jackson Laboratories, Bar Harbor ME, USA. Solid
pieces of primary tumors (10 mm3) were dipped into
Matrigel (BD Biosciences) and inserted into the #4
mammary fat pads of anesthetized recipient mice using
a 10-gauge trochar. The animals were implanted subcu-
taneously with single silastic pellets containing 17b-
estradiol (2 mg). Tumors were removed at necropsy
from animals when they reached 1 to 1.5 cm in dia-
meter and were treated with 1 mg/ml collagenase IV
(Sigma) at 37 degrees Celsius for one hour. Clinical
descriptions of tumors were: PE 4; ER+(90%)PR+(75%)
HER2-, PK12; ER+(93%)PR+(15%)HER2-, and PK15; ER
+(8%)PR-HER2-. Studies were performed with Institu-
tional Review Board approval and informed consent of
all patients. All animal studies were performed under an
institutional animal care and use committee (IACUC)
approved protocol.
Tumor formation assay
MCF7 cells or 66Cl4 cells serially diluted in 100 μl of 1:1
PBS/Matrigel (#354234, BD Biosciences) were injected
underneath the nipple of the #4 mammary fat pad of six-
week old female NOD/SCID or BALB/c mice. Tumor for-
mation efficiency was monitored weekly by palpation. For
AZD6244 treatment, 1 × 104 MCF7 cells were injected
into the mammary fat pads of six-week old female NOD/
SCID mice. One week post injection, mice were treated by
oral gavage with 25 mg/kg or 50 mg/kg AZD6244 or vehi-
cle (10% EtOh, 10% Cremophor EL, 80% D5W), twice per
day for three days and once per day for the next three
days. Animal studies were performed under an IACUC
approved protocol. The statistical analysis was performed
using Extreme Limiting Dilution Analysis [21].
Metastasis assay
A total of 1 × 106 66cl4/scramble or 66cl4/Six1KD cells
were suspended in 100 μl of (D)MEM and injected into
the mammary fat pad of six-week old female Balb/C
mice. One week post-injection, mice were treated with
50 mg/kg AZD6244 or vehicle by oral gavage, twice per
day for seven days. Three weeks post cell injection, mice
were injected with D-luciferin, and imaged using the
IVIS200 imaging system. Quantitation of luciferase sig-
nal was performed by measuring flux in lungs and axil-
lary lymph nodes of animals and using the LivingImage
version 2.6 software.
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Results
Six1 expression correlates with poor prognosis in luminal
breast cancers, particularly the luminal B subtype
Because Six1 expression induces an EMT both in vitro
and in vivo, a phenotype that is primarily associated
with basal and claudin low breast cancers, we examined
whether its expression was enriched specifically in these
subtypes of breast cancer using the previously combined
779 breast tumor dataset [22] and UNC311 dataset [23].
Both datasets include patients with early stage breast
cancers as well as with locally advanced disease. While
expression of Six1 could be found in all breast cancer
subtypes, to our surprise, the highest levels of Six1
mRNA were found in human epidermal growth factor
receptor 2 (Her2)-enriched and luminal B breast cancers
(Figure 1A). Furthermore, within this large dataset, we
found that Six1 correlates with shortened relapse free
survival when examining all breast cancers (Figure 1B),
but that this correlation is caused primarily by the effect
of Six1 in the luminal breast cancer subtypes, particu-
larly the luminal B subtype (Figure 1B). In fact, high
expression of Six1 does not predict poor prognosis in
other tumor subtypes [See Additional File 1, Figure
S1A]. Importantly, when we performed a univariate ana-
lysis within 243 luminal A tumors and 162 luminal B
tumors, Six1 expression and metastasis rate was signifi-
cantly correlated only in the luminal B subtypes (p =
0.0177). These data suggest that, despite inducing an
EMT-like phenotype, Six1 may, in fact, play a particu-
larly important role in luminal B breast cancers, which
are highly aggressive and refractory to tamoxifen
therapies.
Because previous studies demonstrated a role for Six1
in EMT and in the expansion of the mammary stem cell
populations [12,13], and because Six1 correlates with
poor prognosis primarily in luminal breast cancers, we
reasoned that Six1 may play an important role in the
TIC population within this subtype of breast cancer.
Thus, we examined the expression of Six1 in the putative
TIC population from primary human luminal type breast
cancers that had been xenografted through NOD-scid
IL2Rgnull mice. Human luminal B breast cancer xeno-
grafts (profiled by J. C. Harrell to establish subtype) were
excised from mice and dissociated using collagenase.
Flow cytometry was then performed using the human
TIC surface markers Lin-, CD24 and CD44 [24], which
importantly have also been implicated in TIC characteris-
tics in luminal cancers specifically [25]. Six1 expression
was significantly elevated in the CD24lowCD44+ human
TIC population when compared to the CD24+CD44-
non-stem cell population in the three different xeno-
grafted human tumors examined (Figure 1C, Additional
File 1, Figure S1B).
To determine whether Six1 levels are higher in the
TIC population of cultured luminal breast cancer cell
lines, thus enabling their use for mechanistic studies, we
performed the functional tumorsphere assay to enrich
for TICs in MCF7 and T47D luminal breast cancer cells
[26]. Similar to our observation in human breast cancers
xenografted in mice, we detected significantly higher
Six1 mRNA in secondary tumorspheres from MCF7 and
T47D cells, as compared to their adherent counterparts
[See Additional File 1, Figure S1C and D respectively].
Six1 expression in MCF7 cells leads to differential
regulation of genes found in the breast TIC-gene
signature
Because Six1 expression is increased in TICs of both
xenografted human luminal breast cancers and cell
lines, we directly assessed whether Six1 overexpression
could lead to an expansion of TICs in the MCF7 lumi-
nal mammary carcinoma cell line. Microarray analysis
was performed on previously established MCF7 cell
lines overexpressing Six1 (MCF7-Six1) versus control
MCF7 cells (MCF7-Ctrl) [17] and the gene expression
signatures were compared to human breast TIC signa-
tures published by two independent groups [24,27] (Fig-
ure 2A and Additional File 2, Figure S2A). In both
datasets, genes identified in the signature were differen-
tially regulated in MCF7-Six1 cells when compared to
MCF7-Ctrl cells. These data strongly suggest that Six1
alters the expression of genes associated with the TIC
phenotype.
Overexpression of Six1 increases the percentage of TICs
in MCF7 cells
Since MCF7-Six1 cells display an altered TIC-like gene
signature, we asked whether Six1 increases the overall
percentage of TICs when overexpressed in MCF7 cells.
To test this possibility, we compared the percentage of
TICs between MCF7-Ctrl and MCF7-Six1 cells using
flow cytometry after staining the cells with antibodies
against CD24 and CD44 [28]. We found that MCF7-Six1
cells display a fivefold increase in the CD24lowCD44+
putative breast TICs relative to the MCF7-Ctrl cells (Fig-
ure 2B, Additional File 2, Figure S2B). To determine
whether the increased CD24lowCD44+ population repre-
sents a functional increase in TICs, tumorsphere assays
were performed. Secondary tumorsphere assays, which
measure self-renewal capability, demonstrate that Six1
overexpression results in a two-fold increase in tumor-
sphere formation efficiency (Figure 2C). Because the
tumorsphere assay may lead to aggregation, we addition-
ally performed the assay after plating single cells per well
in 96-well plates to assess TIC activity. As shown in
Additional File 3, Figure S3A, secondary tumorsphere
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Figure 1 Six1 expression correlates with poor prognosis in luminal breast cancer and is high in luminal breast cancer TICs.
(A) Association of Six1 with intrinsic subtype. Box-and-whisker plots are shown for two independent datasets, 779 tumor dataset and UNC311
dataset. P values were calculated with ANOVA. Individual P-values comparing expression of Six1 in luminal B tumors to other subtypes are as
follows: 779 dataset versus Basal = 0.0004, Claudin = 1.43E-6, HER2 = 0.07, LumA = 0.03. UNC311 dataset versus Basal = 0.0089, Claudin = 0.0046,
HER2 = 0.4561, LumA = 0.0388. (B) Relapse free survival curve of Kaplan-Meier analyses with a combined 779 breast tumor data set. Kaplan
Meier curves are shown for all breast cancer subtypes, Luminal A tumors, and Luminal B tumors. (C) Six1 mRNA expression was determined by
RT-PCR, and normalized to Cyclophilin B mRNA. Luminal B patient xenografts PE4, PK12 and PK15 were injected in NOD-scid IL2Rgnull mice, after
which the tumors were excised, CD24+CD44- and CD24low CD44+ populations isolated, and Six1 mRNA levels determined. PE4; ER+(90%)PR
+(75%)HER2-, PT12; ER+(93%)PR+(15%)HER2-, and PT15; ER+(8%)PR-HER2-. ANOVA, analysis of variance; RT-PCR, reverse transcriptase-polymerase
chain reaction.
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assays performed on single cells after sorting demon-
strated that Six1 overexpression results in a 1.5-fold
increase in the efficiency of formation of tumorspheres. It
should be noted that the overall number of MCF7 cells
that can form spheres in a single cell assay is significantly
higher than that in a standard assay, perhaps because cell
aggregation leads to an underestimate of sphere number
in the standard sphere assay. Nonetheless, taken together
these data strongly suggest that Six1 is able to increase
the percentage of functional TICs when overexpressed in
luminal type mammary carcinoma cells.
To determine conclusively whether Six1 overexpres-
sion augments the functional TIC compartment, we
serially diluted MCF7-Six1 or MCF7-Ctrl cells (three
individual clones of each line) and injected them ortho-
topically into NOD/SCID mice. Five weeks after ortho-
topic injection of 104 cells, MCF7-Six1 cells formed
tumors 100% of the time, whereas MCF7-Ctrl cells
formed tumors only 50% of the time. When the number
of cells injected was reduced to 103, 44% of the MCF7-
Six1 formed tumors, whereas only 11% of the MCF7-
Ctrl cells formed tumors (P < 0.001) (Figure 2D and
Supplemental Figure S2C). Together, these data demon-
strate that Six1 overexpression in luminal MCF7 breast
cancer cells significantly increases the tumor initiating
capability of these cells.
Six1 expands the MCF7 TIC population through activating
TGF-b signaling
We have shown that Six1 activates TGF-b signaling [12]
and that the activation of TGF-b signaling by Six1 is
required for its ability to induce EMT and metastasis
[12]. Importantly, activation of TGF-b signaling induces
TICs, providing a strong link between EMT, TICs, and
metastatic disease [28-30]. To assess whether TGF-b
signaling is required for the Six1-induced increase in
TICs, we performed the tumorsphere assay on MCF7-
Ctrl and MCF7-Six1 cells treated with SB431542, a
TGF-b type I receptor kinase inhibitor. SB431542 treat-
ment inhibited TGF-b signaling in both MCF7-Ctrl and
MCF7-Six1 cells [See Additional File 4, Figure S4A];
however, tumorsphere formation efficiency was only
inhibited in MCF7-Six1 cells, but not in MCF7-Ctrl
cells [See Additional File 4, Figure S4B]. These data sug-
gest that Six1-mediated upregulation of TGF-b signaling
is required for the ability of Six1 to increase the func-
tional TIC population, and that Six1-expressing cells are
strongly dependent on this pathway for the induction of
TICs. To eliminate the possibility that the SB431542
may diminish the Six1-induced TIC population via off
target effects, we utilized a second system, in which
MCF7-Six1 cells were stably transfected with a TGF-b
Type II receptor dominant negative construct
(TbRIIDN) [12]. MCF7-Six1/TbRIIDN cells were first
Figure 2 Six1 overexpression leads to an increase in TICs. (A)
Six1 differentially regulates genes in the TIC signature. Microarray
analysis was performed on MCF7-Six1 and Ctrl cells [17]. Expression
data were filtered for probesets included in the CSC gene list from
Shipitsin et al. [24] that had a ‘present’ call in at least 50% of the
microarrays. Genes were clustered using hierarchical clustering. The
color scale represents the expression level of a gene above (red),
below (green), and at (black) the mean expression level of that
gene across all samples. (B) Graph of the percent CD24low CD44+
cells found in MCF7-Six1 and MCF7-Ctrl cells. The graph represents
an average of at least three independent experiments with three
individual clones. Error bars represent mean +/- SEM. P values
represent statistical analysis using a two-tailed t test. (C)
Tumorsphere assays demonstrate that Six1 overexpression increases
functional TICs. Secondary tumorsphere assays performed by plating
cells from the primary tumorsphere in ultra low attachment plates
and culturing for ten days. The graph represents three individual
clones. Error bars represent mean value +/- SEM. P values represent
statistical analysis using a two-tailed t test. The experiments were
performed at least three times. (D) Six1 overexpression in MCF7 cells
promotes tumor initiation in NOD/SCID mice. A total of 105 to 103
MCF7-Ctrl or MCF7-Six1 cells were injected into the #4 mammary fat
pad of six-week old female NOD/SCID mice, and tumor formation
monitored. Data shown from five weeks post injection. Statistical
analysis performed using Extreme Limiting Dilution Analysis. Ctrl
versus.. Six1; P < 0.001. CSC, cancer stem cell; Ctrl, control; SEM,
standard error of the mean; TIC, tumor initiating cell.
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examined to insure that TGF-b signaling was decreased
in the presence of the TbRIIDN using a 3TP-luciferase
reporter assay. As previously demonstrated [12], tran-
scription from the Smad-responsive 3TP-luciferase con-
struct is increased in MCF7-Six1 cells when compared
to MCF7-Ctrl cells, and introduction of the TbRIIDN
inhibits TGF-b signaling in both contexts [See Addi-
tional File 4, Figure S4C]. These cells were then used to
examine the percentage of putative breast TICs
(CD24lowCD44+) in the absence or presence of Six1, and
with or without active TGF-b signaling. MCF7-Six1/
TbRIIDN cells contained a significantly lower percen-
tage of CD24lowCD44+ cells when compared to the
MCF7-Six1/GFP cells (Figure 3A). In contrast, inhibition
of TGF-b signaling in MCF7-Ctrl cells did not signifi-
cantly alter the percentage of putative TICs as measured
by flow cytometry (Figure 3A). Furthermore, tumor-
sphere formation efficiency was also dramatically
reduced when TGF-b signaling was inhibited in the
MCF7-Six1 cells, but not in MCF7-Ctrl cells (Figure
3B). Together, these data demonstrate that Six1 overex-
pressing cells are uniquely sensitive to inhibition of
TGF-b signaling, and that they depend on the TGF-b
pathway to augment the TIC population.
TGF-b signaling is partially required for Six1-induced
tumor initiation in vivo
To confirm that the TGF-b pathway is required for the
ability of Six1 to initiate tumors in vivo, we injected
MCF7-Ctrl/GFP, MCF7-Six1/GFP, or MCF7-Six1/
TbRIIDN cells at limiting dilutions into the mammary
fat pads of NOD/SCID mice, as described above. As
expected, the MCF7-Six1 cells were dramatically more
efficient at inducing tumors than the MCF7-Ctrl cells,
which in this experiment was most evident at 102 cells
(P < 5E-08) (Figure 3C, and Additional File 4, Figure
S4D). The greater efficiency of tumor formation in this
experiment as compared to that shown in Figure 2D is
likely due to the fact that one clonal isolate was used
from MCF7-Ctrl and MCF7-Six1 cells, as opposed to
three of each, since one isolate needed to be chosen to
make the TbRIIDN cells. Interestingly, the MCF7-Six1/
TbRIIDN cells formed tumors at an intermediate level
between MCF7-Ctrl and MCF7-Six1 cells (Ctrl versus
TbRIIDN, P = 0.067; Six1 versus TbRIIDN, P < 5E-05).
These data suggest that the TGF-b pathway is a critical,
but not the only pathway, required by Six1 to mediate
tumor initiation in vivo. Tumor size was not signifi-
cantly different between the MCF7-Six1/GFP and
MCF7-Six1/TbRIIDN [See Additional File 4, Figure
S4E], suggesting that the decrease in tumor initiation
Figure 3 Six1 is dependent on TGF-b and MEK/ERK signaling to
increase TICs. (A) Inhibition of TGF-b signaling leads to reduction
of the CD24low CD44+ TICs in MCF7-Six1 cells. The graph represents
an average of at least three experiments. Error bars represent mean
+/- SEM. P values calculated with a two-tailed t test. (B) Inhibition of
TGF-b signaling reverses Six1-dependent increases in tumorsphere
formation. Representative secondary tumorsphere assay at d10.
Experiments were performed at least three times. Error bars
represent mean +/- SEM. P values calculated using a two-tailed t
test. (C) Six1 expands the MCF7 TIC population through TGF-b
signaling. Decreasing cell numbers were injected into the #4
mammary fat pad of six-week old female NOD/SCID mice, and the
mice were monitored for tumor formation (five week data shown).
Statistical analysis was performed using Extreme Limiting Dilution
Analysis: Ctrl versus Six1, P < 5E-08; Ctrl versus TbRIIDN, P = 0.067;
Six1 versus TbRIIDN, P < 5E-05. (D) Six1 activates ERK
phosphorylation. Western blot analysis performed on lysates from
three MCF7-Ctrl and MCF7-Six1 clones using anti-pERK (1:1000) and
anti-total ERK (1:1000). (E) Six1 increases ERK phosphorylation in part
through TGF-b signaling. The TGF-b type I receptor kinase inhibitor,
SB431542, partially represses Six1-mediated ERK phosphorylation.
MCF7-Ctrl and MCF7-Six1 cells (three clones each) were treated with
1 μM SB431542 or DMSO for 48 hours after which Western blot
analysis was performed and analyzed with Quantity one software
(v4.6.2 Bio-Rad). The graph is an average of at least three
experiments with three clones. Error bars represent mean +/- SEM.
P values calculated using a two-tailed t test. Ctrl, control; ERK,
extracellular growth factor receptor; MEK, mitogen activated protein
kinase; SEM, standard error of the mean; TGFb, transforming growth
factor b; TIC, tumor initiating cell.
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was not merely a consequence of decreased growth rates
of the tumor cells. Upon re-examination of the tumor-
sphere data, an intermediate phenotype was also observed
when comparing MCF7-Ctrl/GFP to MCF7-Six1/
TbRIIDN (Figure 3B, P < 0.0001). Overall, these data
strongly suggest that the Six1-induced increase in TICs is
in part dependent on the TGF-b pathway, but that Six1
may affect other TIC-inducing pathways as well.
Six1 increases the TIC population via activating the MEK/
ERK signaling pathway
Since TGF-b signaling is likely not the only mechanism
by which Six1 induces TICs, we examined whether Six1
induces other signaling pathways that may be linked to
TICs. The Raf/MEK/ERK signaling pathway has been
linked to metastasis [31], EMT [32], and to cancer stem
cells/tumor initiating cells [33]. Therefore, western blot
analysis was performed to examine phosphorylation of
ERK, which is a measure of activated ERK, in MCF7-
Ctrl and MCF7-Six1 cells. Interestingly, a clear induc-
tion of pERK was seen with Six1 overexpression (Figure
3D). Since MEK/ERK kinases are known to be down-
stream of TGF-b in the non-canonical pathway [34], we
determined whether activation of ERK in the MCF7-
Six1 cells is dependent on TGF-b signaling by treating
the cells with SB431542, which is known not to target
ERK signaling directly [35]. Addition of SB431542 par-
tially diminished the Six1-induced increase in pERK, but
did not bring it back down to control levels (Figure 3E
and Additional File 4, Figure S4F). Additionally,
SB431542 treatment of MCF7-Ctrl cells diminished
pERK levels. Together, these data suggest that MCF7
cells are in part dependent on TGF-b signaling to
induce ERK signaling, but that Six1 impinges on MEK/
ERK signaling in a manner that is independent of TGF-
b. Thus, the data demonstrate that Six1 activates the
MEK/ERK pathway via multiple mechanisms.
MEK/ERK signaling is required to mediate the Six1-
induced increase in breast TICs
Since Six1 leads to an increase in ERK activation, we
examined whether inhibition of MEK/ERK signaling,
using the MEK1/2 kinase inhibitor U0126, decreases the
ability of Six1 to enhance TICs. Western blot analysis
was performed to examine phosphorylation of ERK and
total ERK in lysates taken from MCF7-Ctrl and MCF7-
Six1 cells treated with U0126 or with vehicle. U0126
inhibited phosphorylation of ERK both in MCF7-Ctrl
and MCF7-Six1 cells [See Additional File 5 Figure S5A].
Flow cytometry assays to detect CD24lowCD44+ TICs in
U0126 MCF7-Six1 treated cells as compared to vehicle
treated cells showed a significant decrease in the TICs,
bringing the percentage almost back down to that
observed in MCF7-Ctrl cells (Figure 4A). In concert
with the decrease in CD24lowCD44+ cells, tumorsphere
formation efficiency was also decreased in MCF7-Six1
cells treated with U0126, to levels comparable to those
observed in MCF7-Ctrl cells, suggesting that the MEK/
ERK pathway is required for the ability of Six1 to
Figure 4 Inhibition of MEK1/2 signaling attenuates Six1-
induced increases in TICs. (A) Inhibition of MEK1/2 with U0126
reduces the CD24low CD44+ TIC population. Cells were treated
with10 μM U0126 for ten days. The graph represents an average of
at least three experiments with three clones. Error bars represent
mean +/- SEM. P values calculated using a two-tailed t test. (B)
Inhibition of MEK1/2 with U0126 reduces secondary tumorsphere
formation in MCF7-Six1 cells. Representative secondary tumorsphere
assays at d10. The cells were treated with 10 μM U0126 throughout
the assay. Experiments were performed at least three times. Error
bars represent mean +/- SEM. P values calculated using a two-tailed
t test. (C) Inhibition of MEK1/2 reverses b-catenin dependent
transcription, as measured using a b-catenin responsive promoter
(Top-flash) after normalization to renilla luciferase. Experiments were
performed at least three times. Error bars represent mean +/- SEM.
P values calculated using a two-tailed t test. (D) Inhibition of MEK1/
2 by AZD6244 decreases tumor formation efficiency in NOD/SCID
mice. A total of 104 MCF7-Six1 or MCF7-Ctrl cells (three clones each)
were injected underneath the nipple of the fourth mammary gland
of six-week old female NOD/SCID mice. One week post injection,
the mice were treated with AZD6244 by oral gavage twice per day
for three days and once/day for the following three days (vehicle,
25 mg/kg or 50 mg/kg) and were monitored weekly for tumor
formation (five week data shown). Statistical analysis: Extreme
Limiting Dilution Analysis. Six1 with vehicle versus Six1 with
AZD6244 25 mg/kg, P < 0.05; Six1 with vehicle versus Six1 with
AZD6244 50 mg/kg, P < 0.005. ERK, extracellular growth factor
receptor; MEK, mitogen activated protein kinase; SEM, standard error
of the mean; TIC, tumor initiating cell.
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increase the functional TIC population (Figure 4B).
Because TICs and EMT go hand in hand [28], we asked
whether MEK/ERK signaling may also impinge on the
EMT induced by Six1 [12]. Indeed, U0126 treatment
reversed the re-localization of E-cadherin and b-catenin
observed in Six1 overexpressing cells, back to the levels
in control cells [See Additional File 5, Figure S5B, C].
Moreover, inhibition of MEK/ERK with U0126 also
reversed the ability of Six1 to induce transcriptional
activation of the b-catenin TOP-FLASH reporter (Figure
4C). Overall, our data demonstrate that MEK/ERK sig-
naling enhanced by Six1 is important for the induction
of characteristics of EMT and TICs in MCF7 cells.
Inhibition of MEK/ERK signaling decreases the tumor
initiation capability of MCF7-Six1 cells
Because the commonly used MEK1/2 inhibitor, U0126,
is not suitable for in vivo studies due to its associated
toxicity [36], we instead used the highly specific MEK
inhibitor, AZD6244, for studies performed in animals.
AZD6244 does not perturb ATP-binding, but specifically
blocks MEK activity [36]. It has been used in phase II
clinical trials for patients with melanoma, non-small cell
lung cancer, pancreatic cancer, breast cancer, colorectal
cancer, as a single agent or in combination with other
drugs. AZD6244 decreased secondary tumorsphere for-
mation efficiency in MCF7-Six1 cells with equal potency
to U0126 [See Additional File 5, Figure S5D, E]. When
mice injected orthotopically with different concentra-
tions of MCF7-Six1 cells were treated with AZD6244
(orally administered at 50 mg/kg/day or 100 mg/kg/day
or vehicle), tumor initiation was significantly decreased
up to five weeks post injection (vehicle versus AZD6244
25 mg/kg, P < 0.05; vehicle versus AZD6244 50 mg/kg,
P < 0.005) (Figure 4D, Additional File 5, Figure S5F).
However, treatment of MCF7-Ctrl injected mice with
AZD6244 also significantly inhibited tumor initiation,
suggesting that the MEK/ERK pathway is critical in
tumor initiation in multiple contexts and that increased
Six1 amplifies a pathway that is already required for
tumor initiation. Regardless, inhibition of the MEK/ERK
pathway may be a promising therapy to target TICs in
luminal breast cancer. More importantly, these data sug-
gest that targeting Six1 directly may also be an effective
inhibitor of TICs as multiple pathways regulating the
TIC phenotype including ERK and TGF-b pathways are
activated by Six1.
Endogenous Six1 regulates tumor initiation in an
immunocompetent mouse model of breast cancer
Although it is clear that Six1 overexpression leads to an
increase in TICs, it is important to examine whether
Figure 5 Six1 is critical for ERK signaling and for tumor
initiation in BALB/c mice. (A) Western blot analysis demonstrates
that introduction of a Six1 shRNA leads to an efficient decrease in
Six1 protein in the cells. Nuclear extracts were isolated from 66cl4
control and Six1 knockdown cells and western blot analysis was
performed with an anti-Six1 antibody (1:1000). An anti-HDAC
antibody was used as a loading control. (B) AZD6244 treatment
(second lane) and knockdown of Six1 (third and fourth lane)
decreases pERK expression in 66cl4 cells. The cells were treated with
10 μM AZD6244 or vehicle for two hours. Whole cell lysates were
used for Western blot analysis along with anti-pERK (1:1000) and
anti-total ERK (1:1000) antibodies. (C) 66cl4 scramble control or
Six1KD cells were serially diluted and then injected into the fourth
mammary fat pad of six-week old female BALB/c mice. Mice were
monitored for tumor initiation weekly. Data shown are from five
weeks post injection of tumor cells. (D) A total of 106 66cl4/
scramble or 66cl4/Six1KD cells were injected into the fourth
mammary fat pad. One week post injection, mice were treated by
oral gavage with vehicle or AZD6244 (50 mg/kg or vehicle twice
per day for seven days). After injection of 150 mg of luciferin/kg
into the mice, IVIS imaging was used to quantitate the metastastic
burden every week. Error bars represent mean value +/- SEM. P
values represent statistical analysis between 66cl4/scramble vehicle
treated and AZD6244 treated mice, 66cl4/scramble vehicle treated
and 66c14/Six1 KD vehicle treated mice, using a two-tailed t test.
ERK, extracellular signal-regulated kinase; SEM, standard error of the
mean; shRNA, short hairpin RNA.
Iwanaga et al. Breast Cancer Research 2012, 14:R100
http://breast-cancer-research.com/content/14/4/R100
Page 9 of 14
inhibition of Six1 could actually decrease the TIC popu-
lation, thus affording a novel avenue by which TICs
could be targeted, particularly in an immune-competent
model. We thus performed shRNA-mediated knock-
down of Six1 in the highly metastatic 66Cl4 mouse
mammary carcinoma cell line (Figure 5A), which
expresses high levels of endogenous Six1 and metasta-
sizes from the orthotopic site when injected into syn-
geneic immunocompetent BALB/c mice [37]. Consistent
with our results in MCF7 cells, we found that Six1 also
modulates ERK signaling in this endogenous context,
since knockdown (KD) of Six1 led to a decrease in
pERK levels (Figure 5B).
To examine in vivo tumor formation efficiency in the
context of Six1 KD, we performed the serial dilution/
transplant assay using, in this case, an allograft model.
Decreasing numbers of 66Cl4 scramble control KD cells
(66cl4/scram), 66Cl4-Six1 KD1 and 66Cl4/Six1 KD2
cells were injected orthotopically into the mammary
glands of BALB/c mice and tumor formation was moni-
tored weekly. A significant decrease in tumor formation
was observed with both Six1 KD cell lines, which was
more pronounced at lower cell numbers (Figure 5C,
Additional File 6, Figure S6A). Since Six1 is also impor-
tant for cell cycle progression and the knock down of
Six1 affects cell proliferation [38], we followed the
experiment for eight weeks in the group of mice
injected with 102 cells and 10 cells, and found that the
tumor formation efficiency was not significantly altered
from the five week time-point (not shown). These data
suggest that the decrease in tumor initiation observed is
not merely due to the difference in proliferation between
66Cl4 and 66Cl4/Six1KD, but may, at least in part, occur
due to an alteration in of the number of TICs.
Because breast TICs are also associated with meta-
static dissemination, we examined whether inhibition of
the MEK1/2 kinase decreases not only tumor formation
efficiency, but also metastasis. We thus performed an
orthotopic metastasis assay as follows: 106 66cl4 cells
were injected into the fourth mammary gland of BALB/
c mice [37]. After one week, to allow the cells sufficient
time to begin to form micrometastases in the lung [37],
the mice received oral AZD6244 (or vehicle) two times
daily at 50 mg/kg for seven additional days. The mice
were imaged weekly using IVIS imaging. Intriguingly,
even at three weeks post injection (and thus one week
following cessation of treatment with AZD6244), the
total metastatic burden (monitored by total flux in the
lung and the axillary lymph nodes), was about five times
less in AZD6244-treated relative to vehicle control trea-
ted animals (Figure 5D). Indeed, the decrease in meta-
static burden (measured at three weeks) in response to
MEK1/2 inhibition was similar to that observed with
Six1 KD (Figure 5D). It should be noted that because
the mice were treated with AZD6244 one week after
cell injection, the effects of the drug could be on either
metastatic dissemination and/or on metastatic
outgrowth.
Importantly, in this experiment we also observed that
AZD6244 treatment modestly decreased primary tumor
size when compared to the control group, although this
difference did not reach statistical significance, whereas
the Six1 knockdown did reach statistical significance
[See Additional File 6, Figure S6B]. Thus, it is possible
that decreases in primary tumor burden influence the
extent of metastasis both with MEK inhibition and Six1
inhibition, although Six1 inhibition has recently been
shown to influence metastasis independent of primary
tumor size [39]. Nonetheless, taken together, these data
suggest that Six1 expression, and the MEK/ERK path-
way, activated downstream of Six1, are important for
tumor initiation, tumor burden, and subsequent metas-
tasis in an allograft mammary tumor mouse model.
pERK significantly correlates with Six1 expression in
human breast cancer
Our results strongly suggest that Six1 increases TICs
through activation of both TGF-b and MEK/ERK signal-
ing in breast cancer cells. Indeed, we previously reported
that Six1 and nuclear localization of the TGF-b effector
Smad3 were significantly correlated in human breast
cancer samples [12]. To examine whether ERK pathway
activation also correlates with Six1 in human breast can-
cer, 72 human breast cancer tissues were stained with
an anti-Six1 and anti-pERK antibody (Figure 6A, B).
The expression levels of nuclear Six1 and levels of ERK
phosphorylation (both nuclear and cytoplasmic pERK,
intensity times percent of area) were significantly corre-
lated (P < 0.05), These findings demonstrate that Six1
correlates with pERK in human breast cancer, and sug-
gest that activation of ERK by Six1 may lead to expan-
sion of TICs and to increased tumor aggressiveness.
Discussion
In this paper we show that Six1 enhances a tumor
initiating phenotype and that its expression is specifi-
cally associated with worsened prognosis in luminal B
tumors. Within the paper, we use numerous means to
conclusively demonstrate that Six1 induces a TIC phe-
notype through both TGF-b and ERK signaling, includ-
ing examination of surface markers, tumorsphere
assays, and in vivo tumor initiating assays. It should be
noted that we have found that while Six1 enhances
TICs as measured by in vivo tumor initiation in all
contexts examined, we have found that changes in flow
cytometric TIC markers are not always consistent with
in vivo TIC results. These data suggest that the surface
markers, while frequently used, are imperfect indicators
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of an in vivo tumor initiating phenotype, and that one
should always use in vitro assays coupled with in vivo
assays to make firm conclusions regarding TIC
phenotypes.
Interestingly, while Six1 overexpressing luminal cells
are uniquely dependent on TGF-b signaling to increase
TIC populations in vitro, they are no more dependent
than control cells on MEK/ERK signaling to induce
some TIC characteristics in vitro, and for tumor initia-
tion in vivo. Instead, Six1 overexpression increases the
magnitude of MEK/ERK signaling. These data allow us
to speculate that the MEK inhibitor, AZD6244, may be
an attractive drug to target the luminal (and perhaps
other) breast cancer TICs in any cells in which MEK/
ERK signaling is active, but that Six1 overexpressing
cells may require increased levels of the drug to accom-
modate the enhanced MEK/ERK signaling observed in
those cells.
The mechanism by which Six1 activates MEK/ERK
signaling is still unknown. It is known that TGF-b can
activate the MEK/ERK pathway through a non-canonical
pathway [32,34,40,41]. However, while our data indicate
that Six1 may partially regulate MEK/ERK signaling
downstream of TGF-b, it is not clear that this mechan-
ism is solely responsible. Instead, we favor the hypoth-
esis that Six1 regulates MEK/ERK signaling via TGF-b
signaling as well as via regulating additional pathways,
and that the induction of TGF-b signaling and MEK/
ERK signaling together contribute to the ability of Six1
to induce TICs.
Both TGF-b signaling and MEK signaling have been
implicated in EMT and TICs, and thus, Six1 upregula-
tion of these pathways is consistent with the ability of
Six1 to impart a TIC phenotype (Figure 5). Indeed,
TGF-b signaling is an inducer of EMT and TICs in a
variety of cells [12,24,28,42,43] and, in normal murine
mammary gland epithelial cells, MEK/ERK signaling is
required for TGF-b induced EMT [41]. MEK/ERK sig-
naling has also been implicated in the induction of stem
cell characteristics independent of TGF-b signaling. For
example, inhibition of MEK/ERK signaling results in dif-
ferentiation of human embryonic stem cells and human
pluripotent stem cells into functional CD34+ progenitor
cells [44], suggesting that MEK/ERK signaling is impor-
tant for the maintenance of stem cell properties.
Furthermore, MEK/ERK signaling has been implicated
not only in normal stem cells, but in TICs [33].
Finally, our data demonstrate that Six1 expression in
human tumors correlates both with activated TGF-b sig-
naling and with activated ERK. It should be noted that
the Six1 antibody used in these experiments was gener-
ated against a conserved region of Six1 and it may thus
cross-react with other Six family members; therefore we
can only confidently state that Six family member
expression correlates with activated ERK. However, as
Six1 is strongly correlated with prognosis in human
breast cancers, and as its overexpression is observed in
as many as 50% to 90% of breast cancers, it is likely that
the staining is reflective of Six1 expression. In addition,
we demonstrate that Six1 mRNA correlates with poor
prognosis specifically in luminal type breast cancers.
Taken together, these data suggest that combining ERK
and TGF-b inhibitors may be an effective means of
eliminating TICs in luminal type breast cancers, particu-
larly in luminal B breast cancers.
Figure 6 pERK levels significantly correlate with Six1
expression in human breast cancer. (A) Tumor arrays containing
72 human breast cancer samples were stained with anti-Six1 (1:100
Atlas antibodies) and anti-pERK (1:100 Phosphosolutions) antibodies.
The immunostained arrays were scored in a blinded manner by a
pathologist (PJ). Patients whose tumors have high levels of nuclear
Six1, also have high levels of pERK, as assessed using the anti-Six1
antibody (nuclear Six1 intensity) and pERK expression (both nuclear
and cytoplasmic, intensity times area). Error bars represent mean
value +/- SEM. P values represent statistical analysis between no-
Six1 expression and high-Six1 expression samples using a two-tailed
t test. (B) Representative images of no Six1 and high Six1 expressing
tumors, and of pERK staining in the same tumors. pERK,
phosphorylated extracellular signal-regulated kinase; SEM, standard
error of the mean.
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Conclusions
We show for the first time that Six1 expression correlates
with poor prognosis in luminal breast cancers and, most
significantly, in the aggressive luminal B subtype. We
demonstrate that Six1 is overexpressed in the CD24low/
CD44+ TIC population from human luminal breast can-
cers, and that it can induce TICs when overexpressed in
luminal breast cancer cells via its ability to activate both
TGF-b and ERK signaling. We further show that endo-
genous Six1 can enhance tumor initiation in an immuno-
competent mouse model, and in this context, where ERK
signaling is regulated by Six1, inhibition of ERK signal-
ling, dramatically decreases metastasis. Finally, we show
for the first time that Six1 correlates with p-ERK in
human breast tumors, suggesting that this mechanism is
relevant to the human disease.
Additional material
Additional file 1: Figure S1. Six1 is enriched in the TIC population
of luminal tumors. (A) Relapse free survival curve of Kaplan-Meier
analyses with a combined 779 tumor data set. Kaplan Meier curves are
shown for Basal tumors, Claudin low tumors and Her2 positive tumors.
(B) Flow cytometry was performed on the luminal B patient xenografts
PK12, PK15 and PE4 following staining of the cells with antibodies that
recognize CD24 and CD44. (C and D) The levels of Six1 mRNA are
increased in MCF7 (B) and T47D (C) secondary tumorspheres as
compared to the parental cells. Error bars represent mean value +/- SEM.
P values represent statistical analysis using a two-tailed t test. The
experiments were performed at least three times.
Additional file 2: Figure S2. Six1 overexpression enhances TIC
characteristics. (A) Six1 differentially regulates genes in the tumor
initiating cell signature. The cancer stem cell/tumor initiating cell gene
list was obtained from Liu et al. [45]. Microarray data from the MCF7-
control and MCF7-Six1 expressing clones were filtered for genes included
in the cancer stem cell/tumor initiating cell gene list and expression
values across the samples were hierarchically clustered. The included
gene expression data represents those genes that are consistently
regulated across the clones. The color scale represents the expression
level of genes above (red), below (green), and at (black) the mean
expression level of that gene across all samples. (B) Six1 overexpression
leads to an increase in tumor initiating cell characteristics. Flow
cytometry was performed on MCF7-Six1 and MCF7-Ctrl cells following
staining of the cells with antibodies that recognize CD24 and CD44. The
boxed region represents the CD24low CD44+ TIC population. (C) Six1 over
expression in MCF7 cells promotes tumor initiation in NOD/SCID mice.
MCF7-Ctrl or MCF7-Six1 cells (105, 104 and 103) were injected into the
number 4 mammary fat pad of six-week old female NOD/SCID mice, and
the mice were then palpated weekly for tumor formation. Data shown
are from two to four weeks post injection.
Additional file 3: Figure S3. Single cell tumorsphere assays
demonstrate that Six1 overexpression increases the functional
tumor initiating population. (A) Single cell tumorsphere assays
demonstrate that Six1 overexpression increases the functional tumor
initiating population. Secondary tumorsphere assays were performed by
plating single cells from the primary tumorsphere in 96-well ultra low
attachment plates and culturing for ten days. The graph represents three
individual clones. Error bars represent mean value +/- SEM. P values
represent statistical analysis using a two-tailed t test. (B) Representative
images of tumorspheres.
Additional file 4: Figure S4. TGF-b signaling is in part required for
the ability of Six1 to induce TICs and pERK signalling. (A) SB431542
inhibits TGF-b signaling in both MCF7-Ctrl and MCF7-Six1 cells, as
assessed by TGF-b responsive promoter 3TP-luciferase activity after
normalizing to renilla-luciferase. Error bars represent mean value +/- SEM.
P values represent statistical analysis using a two-tailed t test. The
experiments were performed at least three times. (B) Inhibition of TGF-b
signaling by SB431542 reverses tumorsphere forming efficiency in MCF7-
Six1 cells back to levels observed in the control cells. Representative
secondary tumorsphere assay was shown after ten days of culture. The
experiments were performed at least three times. Error bars represent
mean value +/- SEM. P values represent statistical analysis using a two-
tailed t test. (C) TbRIIDN inhibits TGF-b signaling in both MCF7-Ctrl and
MCF7-Six1 cells, as assessed using the TGF-b responsive promoter 3TP-
luciferase activity after normalizing to renilla-luciferase. Error bars
represent mean value +/- SEM. P values represent statistical analysis
using a two-tailed t test. The experiments were performed at least three
times. (D) Six1 expands the MCF7 TIC population through activating TGF-
b signaling. Decreasing numbers of MCF7-Six1, MCF7-Six1/TbRIIDN or
MCF7-Ctrl cells were injected into the number 4 mammary fat pad of
six-week old female NOD/SCID mice, and the mice were then palpated
weekly for tumor formation. The data from two, three and four weeks
post injection of tumor cells are shown. (E) Tumor volumes do not differ
between MCF7-Six1/GFP and MCF7-Six1/TbRIIDN groups. Tumor volumes
were measured five weeks post injection. The data shown are taken from
tumors that formed in the group of mice injected with 103 cells. The
tumor size was not significantly different between the MCF7-Six1/GFP
and MCF7-Six1/TbRIIDN. P values represent statistical analysis using 1 way
ANOVA. (F) The TGF-b type I receptor kinase inhibitor, SB431542, partially,
but not completely, represses ERK phosphorylation activated by Six1.
MCF7-Ctrl and MCF7-Six1 cells (three clones each) were treated with 1
μM SB431542 or vehicle (DMSO) for 48 hours after which whole cell
lysates were collected and Western blot analysis was performed for p-
ERK. The quantification is shown in Figure 3(E).
Additional file 5: Figure S5. MEK1/2 inhibitors inhibit EMT and TIC
characteristics. (A) The MEK1/2 inhibitor U0126 decreases pERK in
MCF7-Six1 and MCF7-Ctrl cells. MCF7-Ctrl and MCF7-Six1 (three individual
clones each) were treated with 10 μM U0126 or vehicle (DMSO) for two
hours. The whole cell lysates were used to perform western blot analysis
using anti-pERK (1:1000) and anti-total ERK (1:1000) antibodies. (B and C)
U0126 inhibits the relocalization of E-cadherin (B) and b-catenin (C)
observed with Six1 overexpression. Graphs represent quantitation of
Western blots examining the soluble versus insoluble E-cadherin and b-
catenin. The data represent mean value +/- SEM. P values represent
statistical analysis using a two-tailed t test. (D) The MEK1/2 inhibitor
AZD6244 decreases pERK in MCF7-Six1 and MCF7-Ctrl cells. MCF7-Ctrl
and MCF7-Six1 (three individual clones each) cells were treated with 10
μM AZD6244 or vehicle (DMSO) for two hours. Whole cell lysates were
extracted and used to perform Western blot analysis with anti-pERK
(1:1000) and anti-total ERK (1:1000) antibodies. (E) Inhibition of MEK1/2
with AZD6244 dramatically reduces the secondary tumorsphere
formation of MCF7-Six1 cells. Representative secondary tumorsphere
assay is shown after ten days of culture. The experiments were
performed at least three times. Error bars represent mean value +/- SEM.
P values represent statistical analysis using a two-tailed t test. (F)
Inhibition of MEK1/2 by AZD6244 dramatically decreases tumor
formation efficiency in NOD/SCID mice. A total of 106 MCF7-Six1 or
MCF7-Ctrl cells (three individual clones each) were injected underneath
the nipple of the fourth mammary fat pad of six-week old female NOD/
SCID mice. One week post injection, mice were treated with AZD6244 by
oral gavage twice per day for three days and once per day for the
following three days (vehicle, 50 mg/kg/day or 100 mg/kg/day). The
mice were palpated weekly for tumor formation. The data from two,
three and four weeks post injection of tumor cells are shown.
Additional file 6: Figure S6. Six1 KD inhibits both tumor initiation
and metastasis in an immunocompetent model, and the MEK1/2
inhibitor, AZD6244, inhibits primary tumor burden similarly to Six1
KD. (A) Knockdown of Six1 inhibits tumor initiation. 66cl4 scramble
control or Six1KD cells were serially diluted and then injected into the
fourth mammary fat pad of six-week old female BALB/c mice. Mice were
monitored for tumor initiation weekly. The data from two, three and four
weeks post injection of tumor cells are shown. (B) A total of 106 66cl4/
scramble or 66cl4/Six1KD cells were injected into the fourth mammary
fat pad. One week post injection, mice were treated by oral gavage with
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vehicle or AZD6244 at a concentration of 50 mg/kg or vehicle twice per
day for seven days. After injection of 150 mg of luciferin/kg into the
mice, IVIS imaging was used to quantitate the primary burden at three
weeks post injection. Error bars represent mean value +/- SEM. It should
be noted that the signal from a number (5/10) of the scramble control
tumors was saturated at this time point, suggesting that the size of these
tumors may be underestimated. In contrast, only 1/8 of 66cl4/scramble
tumors in the AZD6244 group had saturated signal, and none of the
tumors in the 66cl4/Six1 KD group had saturated signals.
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